المؤلفون: Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic, Lawrence A. Leiter

المصدر: Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-10 (2019)

مصطلحات موضوعية: Alirocumab, Atherosclerotic cardiovascular disease, Type 2 diabetes mellitus, Low-density lipoprotein cholesterol, Dyslipidemia, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12933-019-0951-9Test; https://doaj.org/toc/1475-2840Test

الوصول الحر: https://doaj.org/article/53a9627a85be45229f4df05a5640bc71Test

المؤلفون: Wenjia Wang, Jonas Mandel, Jan Bouaziz, Daniel Commenges, Serguei Nabirotchkine, Ilya Chumakov, Daniel Cohen, Mickaël Guedj, Alzheimer’s Disease Neuroimaging Initiative

المصدر: PLoS ONE, Vol 10, Iss 9, p e0138223 (2015)

مصطلحات موضوعية: Medicine, Science

وصف الملف: electronic resource

العلاقة: http://europepmc.org/articles/PMC4574966?pdf=renderTest; https://doaj.org/toc/1932-6203Test

الوصول الحر: https://doaj.org/article/1b4e159fc6d74b7aab5ad1f2305dbd7fTest

المؤلفون: Vallejo Vaz, Antonio Javier, Lawrence A. Leiter, Stefano del Prato, Marja-Riitta Taskinen, Dirk Müller-Wieland, Maja Bujas-Bobanovic, Alexia Letierce, Jonas Mandel, Rita Samuel, Kausik K. Ray

المساهمون: Universidad de Sevilla. Departamento de Medicina, Regeneron Pharmaceuticals, Inc., Sanofi

مصطلحات موضوعية: Alirocumab, Goal attainment, Low-density lipoprotein cholesterol, Non-high-density lipoprotein cholesterol, Proprotein convertase subtilisin/kexin type 9, Triglycerides

العلاقة: European Journal of Preventive Cardiology, 27 (15), 1663-1674.; https://academic.oup.com/eurjpc/article/27/15/1663/5950574Test; https://idus.us.es/handle//11441/148044Test

الإتاحة: https://idus.us.es/handle//11441/148044Test

المؤلفون: Serguei, Nabirotchkin, Jan, Bouaziz, Fabrice, Glibert, Jonas, Mandel, Julie, Foucquier, Rodolphe, Hajj, Noëlle, Callizot, Nathalie, Cholet, Mickaël, Guedj, Daniel, Cohen

المصدر: Journal of Alzheimer's Disease. 88:1585-1603

مصطلحات موضوعية: Psychiatry and Mental health, Clinical Psychology, Alzheimer Disease, General Neuroscience, Drug Repositioning, Humans, Gene Regulatory Networks, General Medicine, Geriatrics and Gerontology, Genome-Wide Association Study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3689c941909510a2251ed0bd5d8421b6Test
https://doi.org/10.3233/jad-220120Test

المؤلفون: Lawrence A. Leiter, Kausik K. Ray, Antonio J. Vallejo-Vaz, Rita Samuel, Jonas Mandel, Alexia Letierce, Maja Bujas-Bobanovic, Dirk Müller-Wieland, Stefano Del Prato, Marja-Riitta Taskinen

المساهمون: Universidad de Sevilla. Departamento de Medicina, Regeneron Pharmaceuticals, Inc., Sanofi

المصدر: European Journal of Preventive Cardiology

مصطلحات موضوعية: Male, Cardiac & Cardiovascular Systems, Epidemiology, 030204 cardiovascular system & hematology, NON-HDL CHOLESTEROL, Full Research Paper, DISEASE, HYPERCHOLESTEROLEMIA, chemistry.chemical_compound, 0302 clinical medicine, non-high-density lipoprotein cholesterol, 030212 general & internal medicine, Lipoprotein cholesterol, proprotein convertase subtilisin, 2. Zero hunger, Alirocumab, goal attainment, low-density lipoprotein cholesterol, proprotein convertase subtilisin/kexin type 9, triglycerides, Middle Aged, REMNANT CHOLESTEROL, Non-high-density lipoprotein cholesterol, Treatment Outcome, Cardiovascular Diseases, SAFETY, lipids (amino acids, peptides, and proteins), Female, Seasons, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, kexin type 9, Goals, medicine.drug, medicine.medical_specialty, EZETIMIBE, Proprotein convertase subtilisin/kexin type 9, Antibodies, Monoclonal, Humanized, RESIDUAL RISK, 03 medical and health sciences, Ezetimibe, Internal medicine, medicine, Humans, Low-density lipoprotein cholesterol, Triglycerides, Science & Technology, Triglyceride, Dose-Response Relationship, Drug, business.industry, CARDIOVASCULAR-RISK PATIENTS, Non high density lipoprotein cholesterol, Cholesterol, LDL, EFFICACY, Goal attainment, Residual risk, Endocrinology, chemistry, INHIBITOR ALIROCUMAB, Cardiovascular System & Cardiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Biomarkers, Lipoprotein

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec8c6fd395b5c478da5449379641bf48Test
https://pubmed.ncbi.nlm.nih.gov/32188296Test

المؤلفون: Om P. Ganda, Lawrence A. Leiter, Jorge Plutzky, Santosh K. Sanganalmath, Maja Bujas-Bobanovic, Alexia Letierce, Jonas Mandel, Andrew Koren

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Male, Apolipoprotein B, Endocrinology, Diabetes and Metabolism, lipid‐lowering therapy, 030204 cardiovascular system & hematology, Gastroenterology, 0302 clinical medicine, Endocrinology, cardiovascular disease, 030212 general & internal medicine, Randomized Controlled Trials as Topic, Aged, 80 and over, biology, Antibodies, Monoclonal, clinical trial, Middle Aged, 3. Good health, Treatment Outcome, Cardiovascular Diseases, Female, Original Article, lipids (amino acids, peptides, and proteins), medicine.drug, medicine.medical_specialty, dyslipidaemia, Statin, medicine.drug_class, Antibodies, Monoclonal, Humanized, Placebo, 03 medical and health sciences, Ezetimibe, Diabetes mellitus, Internal medicine, Diabetes Mellitus, Internal Medicine, medicine, Humans, Aged, Alirocumab, business.industry, PCSK9, Original Articles, Atherosclerosis, medicine.disease, Clinical Trials, Phase III as Topic, biology.protein, business, Diabetic Angiopathies, Lipoprotein

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cec65022ad60677478520b22de8b81e1Test
https://doi.org/10.1111/dom.13384Test

المؤلفون: Gisle Langslet, Seth J. Baum, Santosh K. Sanganalmath, Christie M. Ballantyne, Michael H. Davidson, Jonas Mandel, Prediman K. Shah, Peter A. McCullough, Andrew Koren

المصدر: The American Journal of Cardiology. 121:940-948

مصطلحات موضوعية: Male, Simvastatin, Atorvastatin, Coronary Disease, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, 0302 clinical medicine, 030212 general & internal medicine, Rosuvastatin Calcium, Anticholesteremic Agents, PCSK9 Inhibitors, Antibodies, Monoclonal, Middle Aged, Stroke, Treatment Outcome, Cardiology, Drug Therapy, Combination, Female, lipids (amino acids, peptides, and proteins), Cardiology and Cardiovascular Medicine, medicine.drug, Adult, Risk, Heterozygote, medicine.medical_specialty, Statin, Maximum Tolerated Dose, medicine.drug_class, Hypercholesterolemia, Antibodies, Monoclonal, Humanized, Placebo, Hyperlipoproteinemia Type II, Peripheral Arterial Disease, 03 medical and health sciences, Internal medicine, medicine, Humans, Rosuvastatin, Aged, Alirocumab, business.industry, Cholesterol, LDL, Atherosclerosis, medicine.disease, Clinical trial, Clinical Trials, Phase III as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bd3536992aeb00e76cbd7b200b8256dTest
https://doi.org/10.1016/j.amjcard.2017.12.040Test

المؤلفون: John Harrison, Philip D. Harvey, Garen Manvelian, Angele Moryusef, Jonas Mandel, Michel Farnier, Henry N. Ginsberg, M. John Chapman, Marwan N. Sabbagh

المساهمون: Neurology

المصدر: European Heart Journal
Harvey, P D, Sabbagh, M N, Harrison, J E, Ginsberg, H N, Chapman, M J, Manvelian, G, Moryusef, A, Mandel, J & Farnier, M 2018, ' No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: A meta-analysis of individual patient data ', European Heart Journal, vol. 39, no. 5, pp. 374-381 . https://doi.org/10.1093/eurheartj/ehx661Test
European Heart Journal, 39(5), 374-381. Oxford University Press

مصطلحات موضوعية: Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Coronary Artery Disease, 030204 cardiovascular system & hematology, Placebo, Antibodies, Monoclonal, Humanized, LDL, PCSK9, 03 medical and health sciences, 0302 clinical medicine, Cognition, Ezetimibe, Clinical Research, Internal medicine, medicine, Humans, 030212 general & internal medicine, Adverse effect, Alirocumab, Aged, Randomized Controlled Trials as Topic, business.industry, Anticholesteremic Agents, Hazard ratio, Antibodies, Monoclonal, Cholesterol, LDL, Middle Aged, Discontinuation, Patient safety, Female, Cholesterol-lowering drugs, Cognitive function, Nervous System Diseases, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, business, Neurocognitive, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c495c73cc4b0556e9c7ca963f8e7c0Test
http://europepmc.org/articles/PMC5837381Test

المؤلفون: Jonas Mandel, Lawrence A. Leiter, Rita Samuel, Dirk Müller-Wieland, Maja Bujas-Bobanovic, Stefano Del Prato, Alexia Letierce, Kausik K. Ray, Bertrand Cariou, Francisco J. Tinahones, Catherine Domenger, Helen M. Colhoun

المصدر: Ray, K K, Del Prato, S, Müller-Wieland, D, Cariou, B, Colhoun, H M, Tinahones, F J, Domenger, C, Letierce, A, Mandel, J, Samuel, R, Bujas-Bobanovic, M & Leiter, L A 2019, ' Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease : analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies ', Cardiovascular diabetology, vol. 18, no. 1, pp. 149 . https://doi.org/10.1186/s12933-019-0951-9Test
Cardiovascular Diabetology
Cardiovascular diabetology 18, 149 (2019). doi:10.1186/s12933-019-0951-9
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-10 (2019)

مصطلحات موضوعية: lcsh:Diseases of the circulatory (Cardiovascular) system, Time Factors, Cardiac & Cardiovascular Systems, Endocrinology, Diabetes and Metabolism, Coronary Disease, Type 2 diabetes, Clinical Trials, Phase IV as Topic, chemistry.chemical_compound, Risk Factors, Multicenter Studies as Topic, 1102 Cardiorespiratory Medicine and Haematology, Randomized Controlled Trials as Topic, Original Investigation, RISK, Anticholesteremic Agents, PCSK9 Inhibitors, Treatment Outcome, SAFETY, Drug Therapy, Combination, lipids (amino acids, peptides, and proteins), Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, medicine.medical_specialty, Statin, Serine Proteinase Inhibitors, medicine.drug_class, Placebo, Antibodies, Monoclonal, Humanized, Endocrinology & Metabolism, Internal medicine, Diabetes mellitus, Type 2 diabetes mellitus, medicine, Humans, Low-density lipoprotein cholesterol, ddc:610, Alirocumab, Dyslipidemias, Science & Technology, Cholesterol, business.industry, PCSK9, Cholesterol, HDL, nutritional and metabolic diseases, Cholesterol, LDL, medicine.disease, Atherosclerosis, EFFICACY, chemistry, Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 2, Cardiovascular System & Hematology, Dyslipidemia, lcsh:RC666-701, Atherosclerotic cardiovascular disease, Cardiovascular System & Cardiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Biomarkers

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9d3a05dee250a4541416b551ab40c13Test
http://hdl.handle.net/11568/1029810Test

المؤلفون: Peter B. Jones, Rita Samuel, Alexia Letierce, Francisco J. Tinahones, Lawrence A. Leiter, Dean G. Karalis, Jonas Mandel, Maja Bujas-Bobanovic

المصدر: Diabetic Medicine

مصطلحات موضوعية: Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Heart Diseases, Endocrinology, Diabetes and Metabolism, Hypercholesterolemia, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Placebo, Antibodies, Monoclonal, Humanized, Diabetes Complications, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Clinical Trials, Phase II as Topic, Ezetimibe, Diabetes mellitus, Internal medicine, Internal Medicine, Diabetes Mellitus, Medicine, Humans, Adverse effect, Research Articles, Alirocumab, Aged, Randomized Controlled Trials as Topic, business.industry, Proportional hazards model, PCSK9, Incidence, Hazard ratio, PCSK9 Inhibitors, Antibodies, Monoclonal, Research: Treatment, Middle Aged, medicine.disease, Treatment, Clinical Trials, Phase III as Topic, Female, Proprotein Convertase 9, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e4afea874ab351a52f408aadd3c367Test
https://pubmed.ncbi.nlm.nih.gov/30183102Test